Clinical trial · no report yet · Phase 3
SunRISe-3
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
- NCT05714202 ↗
- Active not recruiting
- Janssen Research & Development, LLC
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Bladder Cancer
- Interventions
- TAR-200; Cetrelimab; BCG Vesiculture
- Arms
- Treatment Group A: TAR-200 + Cetrelimab · Experimental
- Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture · Active comparator
- Treatment Group C: TAR-200 Alone · Experimental
- Enrollment
- 1,135
- Primary outcomes
- Event-free Survival (EFS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Mar 23, 2023
- Primary completion
- Sep 18, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05714202 · updated Sep 25, 2026